Todays Report: Today, Alder BioPharmaceuticals Inc. (ALDR) Given a $47.00 Price Target at Piper Jaffray Cos.

Today, Alder BioPharmaceuticals Inc. (ALDR) Given a $47.00 Price Target at Piper Jaffray Cos.

Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) has been given a $47.00 price objective by equities research analysts at Piper Jaffray Cos. in a note issued to investors on Friday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Piper Jaffray Cos.’s price target would indicate a potential upside of 75.37% from the stock’s current price.

A number of other equities analysts have also commented on ALDR. BMO Capital Markets reaffirmed a “buy” rating on shares of Alder BioPharmaceuticals in a research report on Tuesday. Zacks Investment Research raised shares of Alder BioPharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 1st. Jefferies Group reaffirmed a “buy” rating and set a $57.00 target price on shares of Alder BioPharmaceuticals in a research report on Sunday, November 20th. Brean Capital assumed coverage on shares of Alder BioPharmaceuticals in a research report on Friday, September 30th. They set a “buy” rating and a $45.00 target price on the stock. Finally, Aegis started coverage on shares of Alder BioPharmaceuticals in a research report on Monday, November 7th. They set a “buy” rating and a $41.00 target price on the stock. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $43.38.

Shares of Alder BioPharmaceuticals (NASDAQ:ALDR) traded up 4.69% during midday trading on Friday, reaching $26.80. 297,293 shares of the company’s stock were exchanged. The firm’s market cap is $1.35 billion. The stock’s 50-day moving average is $28.00 and its 200 day moving average is $29.05. Alder BioPharmaceuticals has a one year low of $15.82 and a one year high of $38.74.

Alder BioPharmaceuticals (NASDAQ:ALDR) last issued its earnings results on Thursday, October 27th. The biopharmaceutical company reported ($0.70) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.85) by $0.15. During the same quarter in the previous year, the business earned ($0.62) EPS. Analysts anticipate that Alder BioPharmaceuticals will post ($3.13) EPS for the current year.

In related news, CEO Randall C. Schatzman sold 8,181 shares of Alder BioPharmaceuticals stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $31.15, for a total transaction of $254,838.15. Following the transaction, the chief executive officer now directly owns 122,949 shares of the company’s stock, valued at $3,829,861.35. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Randall C. Schatzman sold 10,000 shares of Alder BioPharmaceuticals stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $32.48, for a total transaction of $324,800.00. Following the transaction, the insider now directly owns 124,768 shares in the company, valued at $4,052,464.64. The disclosure for this sale can be found here. Corporate insiders own 11.50% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. FMR LLC increased its stake in shares of Alder BioPharmaceuticals by 12.8% in the second quarter. FMR LLC now owns 7,404,134 shares of the biopharmaceutical company’s stock valued at $184,881,000 after buying an additional 840,549 shares during the period. Vanguard Group Inc. increased its stake in shares of Alder BioPharmaceuticals by 40.6% in the second quarter. Vanguard Group Inc. now owns 3,092,518 shares of the biopharmaceutical company’s stock valued at $77,220,000 after buying an additional 893,334 shares during the period. BlackRock Fund Advisors increased its stake in shares of Alder BioPharmaceuticals by 5.7% in the third quarter. BlackRock Fund Advisors now owns 1,854,944 shares of the biopharmaceutical company’s stock valued at $60,787,000 after buying an additional 100,431 shares during the period. BB Biotech AG increased its stake in shares of Alder BioPharmaceuticals by 11.6% in the second quarter. BB Biotech AG now owns 1,685,150 shares of the biopharmaceutical company’s stock valued at $42,078,000 after buying an additional 175,000 shares during the period. Finally, State Street Corp increased its stake in shares of Alder BioPharmaceuticals by 8.0% in the second quarter. State Street Corp now owns 1,291,370 shares of the biopharmaceutical company’s stock valued at $32,237,000 after buying an additional 95,570 shares during the period.

About Alder BioPharmaceuticals

Related posts

Leave a Comment